We investigated six cases of inoperable remnant and recurrent gastric cancer treated with radiotherapy with regard to quality of life (QOL). The radiation dose was from 22 to 70 Gy, with a mean dose of 46 +/- 18 Gy. Four cases could be evaluated. Two were PR and two were NC. No patients could ingest food before radiotherapy, but two became able to eat whole gruel, one half gruel and three water. The mean survival time was 5.5 months and prognosis was not improved. Subjective symptoms such as food passage disturbance were decreased by radiotherapy and QOL was improved. Radiotherapy for patients with inoperable gastric cancer seemed to be effective in improving QOL.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
EX vivo liver resection and auto transplantation for a giant hepatocellular carcinoma: A case report.
Int J Surg Case Rep
December 2024
Pakistan Kidney and Liver Institute and Research Center, Lahore, Pakistan.
Introduction And Importance: The curative options for locally advanced hepatocellular carcinomas involving the vessels are very limited. Ex vivo liver resection and auto transplantation (ERAT) is a novel surgical method, which has been used in the management of such complex liver space occupying lesions, which are rendered conventionally unresectable. This technique involves a complete hepatectomy, extracorporeal hepatic resection on the backbench, and then reimplantation of the remnant hepatic parenchyma.
View Article and Find Full Text PDFTransileocolic Portal Vein Embolization Increases Remnant Liver Volume After Major Hepatectomy.
In Vivo
October 2024
Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Background/aim: Transileocolic portal vein embolization (TIPE) may reduce the risk of liver failure after massive hepatectomy. However, convincing evidence of its usefulness in this regard is yet to be reported. Therefore, this study aimed to investigate the use of TIPE after massive hepatectomy.
View Article and Find Full Text PDFUse of selective internal radiation therapy with yttrium-90 as a bridge to liver resection: a 5-year single-center experience.
J Gastrointest Surg
December 2024
Department of General Surgery, Fiona Stanley Hospital, Perth, Western Australia, Australia; School of Medicine, Curtin University, Perth, Western Australia, Australia.
Background: Selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) has been historically reserved for unresectable liver malignancy. Evidence is emerging for the use of SIRT to increase future liver remnant (FLR), allowing for the resection of previously inoperable disease.
Methods: This was a 5-year retrospective review of all patients undergoing SIRT with Y-90 at a tertiary institute.
Chordoma of the Oropharynx.
Med Arch
March 2024
Otorhinolaryngology Clinic, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
Background: Chordoma is a rare malignant neoplasm that predominantly arises from the axial skeleton, but can also develop in unusual locations. However, there are also rare cases of "NOS" chordoma involving the oropharyx and epithelial-myoepithelial carcinoma of the parotid gland in the same patient. According to contemporary research, chordoma is a rare malignant neoplasm that arises from the embryonic remnants of the notochord.
View Article and Find Full Text PDFHepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM).
BMC Cancer
October 2021
IICD - Sheffield, Sheffield, England.
Background: Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test.
Methods: HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!